CARDINAL HEALTH INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $CAH in the last 30 days.
See all $CAH insider activity →Cardinal Health (CAH) and McKesson (MCK) extended their distribution agreements with CVS Health (CVS) until 2032. Cardinal Health reaffirmed its 2027 adjusted earnings guidance of $12.40-$12.60 per share, while McKesson reiterated its 2027 outlook of $44.20-$45 per share. Both companies' stocks rose on the news, with McKesson up 4.28% and Cardinal Health up 2.94%.
Cardinal Health (CAH) has agreed to extend its pharmaceutical distribution agreement with CVS Health. The deal renewal is significant for investors as it ensures continued revenue from a major client. Financial details were not disclosed. Both companies' stocks may be affected by this long-term partnership.
Cardinal Health (CAH) extended its pharmaceutical distribution agreements with CVS Health through June 2032. The company reaffirmed its fiscal year 2027 non-GAAP EPS guidance of $12.40 to $12.60 and long-term growth range of 12% to 14%. The deal secures a key partnership and provides revenue visibility, though investors should note non-GAAP exclusions and industry pressures.
Over the past 7 days, AlphAI's AI scored 13 news stories mentioning CAH (CARDINAL HEALTH INC). Coverage has skewed bullish: 8 bullish, 5 neutral, and 0 bearish.
Recent CAH coverage spans earnings, financial news and corporate actions.
Guidance reaffirmation and contract extension support the stock.
The extension suggests continued partnership strength, likely supporting Cardinal Health's revenue outlook.
The contract extension provides long‑term revenue visibility and supports the reaffirmed earnings guidance, likely sustaining the stock's current valuation.
Reaffirmed guidance suggests stable earnings outlook, limiting upside but supporting current valuation.
The upcoming earnings release may drive short-term volatility as investors position ahead of the report.
AlphAI scores every news story that mentions CAH with an AI model for sentiment and relevance, and aggregates insider trades from CARDINAL HEALTH INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Cardinal Health (CAH) and McKesson (MCK) extended their distribution agreements with CVS Health (CVS) until 2032. Cardinal Health reaffirmed its 2027 adjusted earnings guidance of $12.40-$12.60 per share, while McKesson reiterated its 2027 outlook of $44.20-$45 per share. Both companies' stocks rose on the news, with McKesson up 4.28% and Cardinal Health up 2.94%.
2 min readCardinal Health (CAH) has agreed to extend its pharmaceutical distribution agreement with CVS Health. The deal renewal is significant for investors as it ensures continued revenue from a major client. Financial details were not disclosed. Both companies' stocks may be affected by this long-term partnership.
1 min readCardinal Health (CAH) extended its pharmaceutical distribution agreements with CVS Health through June 2032. The company reaffirmed its fiscal year 2027 non-GAAP EPS guidance of $12.40 to $12.60 and long-term growth range of 12% to 14%. The deal secures a key partnership and provides revenue visibility, though investors should note non-GAAP exclusions and industry pressures.
2 min readCARDINAL HEALTH INC (CAH) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health DUBLIN, Ohio, October 1, 2026 – Cardinal Health (NYSE: CAH) announced today that it has entered into a binding Letter of Intent to extend its existin
1 min readCardinal Health (CAH) will release its fiscal Q1 2027 results on November 5 before the NYSE opening. A webcast discussion will follow at 8:30 a.m. ET. The company is a distributor of pharmaceuticals and medical products. Details will be available on their Investor Relations page.
1 min readCardinal Health ($CAH) CEO Jason M. Hollar's 2026 compensation was estimated at $22.57M, up 15.94% from 2025. Insiders sold 31 times in the past 6 months, with no purchases. Analysts set a median price target of $245.0, and hedge funds showed mixed portfolio activity.
2 min readCardinal Health (CAH) targets 13%-15% EPS growth, driven by specialty platforms in oncology, urology, and autoimmune care. BioPharma Solutions grew over 30% in fiscal 2026, aiming for $1B revenue by fiscal 2028. The company expects 15%-18% adjusted operating-income growth in fiscal 2027, with contributions from recent acquisitions.
2 min readCardinal Health (CAH) is investing in specialty and at-home healthcare, expanding through acquisitions like Strive Medical and AdaptHealth's diabetes business. The company focuses on automated distribution of high-value products. Fiscal 2026 saw strong cash flow, with $10B target nearly met. Growth in Global Medical Products segment was noted, despite commodity cost pressures.
2 min readCardinal Health (CAH) shares are up 10% year-to-date but down 8% since September. Jim Cramer suggested the decline may be due to a rotation into AI stocks. CAH's Q4 earnings beat estimates, with revenue of $63.67B, though missing expectations. Danaher (DHR) shares are down 7% year-to-date, with Q2 earnings beating estimates but deferring $100M in revenue. CAH's forward P/E is 18.48, lower than DHR's 22.47.
2 min readCardinal Health (CAH) shares rose 1.3% after Q4 results showed adjusted EPS of $2.91, beating estimates, but revenue of $63.7B missed forecasts. The company expects full-year adjusted EPS of $12.40-$12.60. Analysts rate CAH a 'Strong Buy' with a mean price target of $270.88, implying 16.4% upside.
2 min read
